Skip to content

Teva Pharmaceutical Industries LTD (TEVA) stock: revenue, earnings & dividend

Teva Pharmaceutical Industries LTD (TEVA, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener TEVA · NYSE Pharma & Biotech US-NJ

Key figures

Fiscal year
2025
Revenue
17.3 bn $
Revenue growth
4.3 %
Revenue growth 5y (p.a.)
0.7 %
Net income
1.41 bn $
Net margin
8.2 %
Operating margin
12.5 %
Earnings per share (diluted)
1.21 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
40.7 bn $
Equity
7.91 bn $
Equity ratio
19.4 %
Return on equity
17.8 %
Cash
3.56 bn $
Operating cash flow
1.65 bn $
Free cash flow
–
Shares outstanding
1,166,826,784

History

Revenue by fiscal year

2016 21.9 bn $
2017 22.4 bn $
2018 18.3 bn $
2019 16.9 bn $
2020 16.7 bn $
2021 15.9 bn $
2022 14.9 bn $
2023 15.8 bn $
2024 16.5 bn $
2025 17.3 bn $

Net income by fiscal year

2016 329 m $
2017 -16.27 bn $
2018 -2.15 bn $
2019 -999 m $
2020 -3.99 bn $
2021 417 m $
2022 -2.45 bn $
2023 -559 m $
2024 -1.64 bn $
2025 1.41 bn $

Dividend per share

2016 1.36 $
2017 0.85 $
2018 0.00 $
2019 0.00 $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
202517.3 bn $1.41 bn $1.21 $–1.65 bn $
202416.5 bn $-1.64 bn $-1.45 $–1.25 bn $
202315.8 bn $-559 m $-0.50 $–1.37 bn $
202214.9 bn $-2.45 bn $-2.20 $–1.59 bn $
202115.9 bn $417 m $0.38 $–798 m $
202016.7 bn $-3.99 bn $-3.64 $–1.22 bn $
201916.9 bn $-999 m $-0.91 $0.00 $748 m $
201818.3 bn $-2.15 bn $-2.35 $0.00 $2.45 bn $
201722.4 bn $-16.27 bn $-16.26 $0.85 $2.23 bn $
201621.9 bn $329 m $0.07 $1.36 $5.23 bn $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)